Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
BioMonde
Bridgend, Wales, United Kingdom
- Ownership
- Private
- Development stage
- Other
01
Overview
BioMonde is a global leader in larval debridement therapy (MDT), specializing in the production and distribution of sterile larvae (Lucilia sericata) for the treatment of chronic and non-healing wounds. Their flagship product, the BioBag, uses a patented containment system to deliver larvae to the wound bed, where they secrete proteolytic enzymes to liquefy necrotic tissue and eradicate biofilm.
- Therapeutic areas
- HematologyCardiovascularEndocrinologyDermatologyInfectious Diseases
- Modalities
- Live biotherapeutic product therapyDevice
- Industry
- Biotech
02
Partnerships
National Health Service (NHS)BfArMFDA
Beyond the preview
Go deeper on BioMonde.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioMonde.